Pregnancy, Postpartum, Lactation, and Psychedelic-Assisted Therapy in Canada — Why Most Substances Are Contraindicated

Pregnancy and the postpartum period — including the lactation interval — are times of profound mental health vulnerability. Perinatal depression and anxiety affect approximately one in seven Canadian birthing parents; postpartum psychosis, peripartum-onset bipolar disorder, perinatal OCD, and birth-related PTSD are also clinically important presentations. Yet pregnant and breastfeeding patients are explicitly excluded from virtually every pivotal psychedelic-assisted therapy randomized controlled trial, controlled human pregnancy and lactation pharmacokinetic data are limited or absent for psilocybin and MDMA, and Health Canada product monographs for ketamine and esketamine (Spravato) flag pregnancy and lactation cautions explicitly. This article is a Canadian safety hub framing why most psychedelic-assisted therapy is appropriately deferred until after pregnancy and lactation, what first-line perinatal mental health treatments do exist (with strong evidence), what the timeline considerations are for family planning during a psychedelic-assisted therapy course, and where to access perinatal crisis resources in Canada. Honest framing: standard perinatal psychiatric care is foundational, emerging research will inform future practice, and most psychedelic-assisted therapy pathways recommend completion before pregnancy or after weaning.

Key takeaways

• Pregnant and breastfeeding patients are excluded from virtually all psychedelic-assisted therapy RCTs. Goodwin 2022, Carhart-Harris 2021, Mitchell 2021/2023, Anand 2023, and Spravato pivotal program all excluded pregnancy and lactation.
• Health Canada Spravato product monograph: pregnancy not recommended; lactation not recommended.
• Health Canada ketamine product monograph: pregnancy caution; uterotonic effects noted; present in breastmilk (pumping/discarding around dosing required if used).
• Psilocybin in pregnancy and lactation: limited human data; animal studies suggest caution; investigational.
• MDMA in pregnancy and lactation: animal studies show neurodevelopmental concerns; no controlled human pregnancy studies; investigational.
• Postpartum (non-lactation): reverts to standard adult considerations once a safe lactation interval is achieved or breastfeeding is discontinued.
• Postpartum depression first-line: psychotherapy (CBT, IPT), sertraline (the most-studied SSRI in lactation), and specialized perinatal psychiatry — see Postpartum Depression and Psychedelic-Assisted Therapy.
• Bipolar peripartum-onset is common — bipolar contraindication considerations apply to psilocybin/MDMA pathways.
• Antidepressant continuation in pregnancy and postpartum: sertraline is first-line in lactation; paroxetine has specific first-trimester considerations; fluoxetine has a longer half-life with implications for lactation.
• Mother-infant bonding is a foundational treatment outcome — perinatal mental health interventions must support, not interrupt, the dyadic relationship.
• Family planning during a PAT (psychedelic-assisted therapy) course: contraception considerations during dosing windows; integration timeline planning.
• Perinatal crisis resources: provincial maternal mental health services; 9-8-8 Canada Suicide Crisis Helpline; Postpartum Support International; Canadian Perinatal Mental Health Collaborative.

Why pregnancy, postpartum, and lactation are a distinct safety population

Perinatal mental health care is a clinical sub-specialty for sound biological and ethical reasons:

• Two patients, one treatment decision — every medication and intervention decision balances maternal benefit against fetal/neonatal exposure
• Teratogenic windows — organogenesis (weeks 3–8 post-conception) is the highest-risk window for structural malformation; second and third trimesters carry distinct neurodevelopmental and obstetric considerations
• Lactation pharmacokinetics — drug transfer into breastmilk depends on lipid solubility, protein binding, molecular weight, and infant clearance capacity
• Maternal physiology — pregnancy alters drug distribution, metabolism, and clearance; postpartum hormonal shifts affect mood vulnerability
• Mother-infant dyad — treatment outcomes include not only maternal symptoms but also bonding, attachment, and infant developmental trajectory
• Ethical exclusion from research — pregnancy and lactation are routinely exclusion criteria in psychiatric RCTs, leaving a persistent evidence gap that must be acknowledged honestly

Specialized perinatal mental health pathways in Canada

Perinatal mental health care in Canada is delivered through a combination of family physicians, obstetricians and midwives, public health nurses, community perinatal mental health programs, specialized reproductive psychiatry clinics, and inpatient mother-baby units. Primary pathways:

• BC Reproductive Mental Health Program — provincial reproductive psychiatry tertiary care
• Women's College Hospital Reproductive Life Stages Program — Toronto reproductive psychiatry
• CAMH Perinatal Mental Health programs — Toronto tertiary care
• CHU Sainte-Justine and McGill perinatal psychiatry — Quebec
• IWK Reproductive Mental Health Service — Maritimes
• Provincial maternal/perinatal mental health teams — community-based programs vary by province
• Canadian Perinatal Mental Health Collaborative — clinician network and family resources
• Postpartum Support International — international resource with Canadian coordinators

Pregnant or postpartum patients with treatment-resistant illness are appropriately routed through these specialized perinatal psychiatry pathways, not adult psychedelic-assisted therapy clinics.

First-line perinatal mental health treatments — strong evidence base

Perinatal mood and anxiety disorder first-line treatments are well-established. CANMAT perinatal mood disorder guidance, the Wisner KL and colleagues body of work, and the BC Reproductive Mental Health Program clinical pathways provide standard-of-care framing.

Perinatal depression and anxiety

• Cognitive behavioural therapy (CBT) — first-line; substantial perinatal RCT evidence
• Interpersonal therapy (IPT) — particularly evidence-based in postpartum depression
• Mindfulness-based cognitive therapy (MBCT) for relapse prevention
• Group therapy and peer support — postpartum-specific groups widely available
• Sertraline — the most-studied SSRI in lactation; CANMAT and reproductive psychiatry consensus first-line
• Escitalopram, citalopram — additional lactation-compatible options
• Paroxetine — historical first-trimester cardiac concerns; consider continuation vs. switch decisions
• Fluoxetine — long half-life (and active metabolite norfluoxetine) has lactation implications; established but considered with care
• Brexanolone (zuranolone) — newer postpartum-specific neurosteroid options where available
• Specialized perinatal psychiatry for treatment-resistant or complex presentations

Postpartum psychosis

• Psychiatric emergency — typically requires inpatient admission, ideally to a mother-baby unit where available
• Antipsychotics, lithium (with lactation framing), ECT are established treatments
• High suicide and infanticide risk — safety planning is foundational

Peripartum-onset bipolar disorder

• Common — bipolar disorder frequently presents or relapses peripartum
• Mood stabilizer continuation/optimization — lithium, lamotrigine, atypical antipsychotics with reproductive psychiatry oversight
• Bipolar contraindication considerations apply to psilocybin and MDMA pathways

Birth-related PTSD

• Trauma-focused CBT, EMDR — first-line; established perinatal evidence
• Specialized birth-trauma services in many tertiary perinatal centres

These first-line pathways are foundational and must be exhausted (or running concurrently with specialized perinatal care) before any consideration of investigational interventions — including psychedelic-assisted therapy.

For more detail, see Postpartum Depression and Psychedelic-Assisted Therapy, Bipolar Disorder and Psychedelic-Assisted Therapy — Considerations, Antidepressant Tapering and Psychedelic-Assisted Therapy.

The perinatal psychedelic-assisted therapy evidence map — what we have and don't have

Pivotal RCT exclusion criteria

The pivotal psychedelic-assisted therapy randomized controlled trials all excluded pregnant and breastfeeding patients:

• Goodwin GM 2022 COMP001 (psilocybin TRD, NEJM) — pregnancy and lactation excluded
• Carhart-Harris RL 2021 (psilocybin vs escitalopram MDD, NEJM) — pregnancy and lactation excluded
• Mitchell JM 2021/2023 MAPP1/MAPP2 (MDMA-AT for PTSD, Nature Medicine) — pregnancy and lactation excluded
• Anand A 2023 ELEKT-D (ketamine vs ECT TRD, NEJM) — pregnancy excluded
• Spravato (esketamine) pivotal program — pregnancy and lactation excluded

This means the published efficacy and safety evidence base does not extend to pregnant or lactating patients. Any clinical decision involves extrapolation from animal data, limited case reports, and pharmacological reasoning — not direct controlled evidence.

Spravato (esketamine) — Health Canada label

The Health Canada Spravato product monograph specifies that Spravato is not recommended during pregnancy and is not recommended during breastfeeding. The pregnancy section reflects animal data signalling potential concerns and the absence of adequate human controlled data. The lactation section reflects the presence of esketamine in breastmilk and the absence of adequate human safety data in nursing infants.

For more detail, see Spravato Coverage and Pathways.

Off-label ketamine — Health Canada label and lactation considerations

The Health Canada ketamine product monograph (anaesthetic indication) flags pregnancy caution — ketamine has documented uterotonic effects (increased uterine tone), which is obstetrically relevant; historical FDA pregnancy categorization was Category B/C depending on indication and era. Ketamine is present in breastmilk; if ketamine is used during lactation, pumping and discarding milk around dosing windows is the conventional risk-mitigation approach, with timing guided by ketamine's pharmacokinetics and infant age. Adequate controlled lactation pharmacokinetic data are limited.

Implications: ketamine therapy during pregnancy is generally deferred. Ketamine therapy during lactation, if pursued, requires explicit lactation pharmacokinetic discussion with a perinatal psychiatrist or reproductive psychopharmacology specialist, lactation consultant involvement, and a clear pump-and-discard protocol.

Psilocybin — limited human pregnancy and lactation data

There are no published controlled human pregnancy studies and no published controlled lactation pharmacokinetic studies for psilocybin-assisted therapy. Animal data are limited and insufficient to characterize teratogenic or neurodevelopmental risk. Psilocybin SAP applications during pregnancy or lactation would face significant clinical resistance — Health Canada Special Access Program review considers the risk-benefit profile and the existence of alternative treatments, and standard perinatal psychiatry alternatives exist for the principal indications.

For more detail, see Psilocybin Therapy in Canada.

MDMA — animal neurodevelopmental concerns and no human pregnancy controlled studies

Animal studies of MDMA show neurodevelopmental concerns — prenatal MDMA exposure in rodent models is associated with effects on serotonergic neurodevelopment and behavioural outcomes. No controlled human pregnancy studies of MDMA-assisted therapy have been conducted. The MotherToBaby teratogenicity database includes recreational MDMA exposure data which carries substantial confounding (polysubstance, dose uncertainty) but does not provide reassurance for clinical MDMA-assisted therapy use in pregnancy.

Implications: MDMA-assisted therapy in pregnancy and lactation is contraindicated under current evidence. SAP applications would face significant clinical resistance.

For more detail, see MDMA-Assisted Therapy in Canada.

Lactation considerations — substance by substance

For more detail, see Ketamine Therapy in Canada.

Antidepressant continuation and tapering — pregnancy and postpartum

Antidepressant decisions in pregnancy and postpartum are never simple discontinuation choices — untreated maternal depression carries its own substantial risks (preterm birth, low birth weight, impaired bonding, postpartum exacerbation). CANMAT perinatal guidance and the Wisner KL body of work emphasize shared decision-making with explicit framing of:

• Sertraline: most-studied SSRI in lactation; first-line in pregnancy and postpartum where SSRI indicated
• Paroxetine: historical first-trimester cardiac concerns; ongoing exposure decisions weigh continuation vs. switch
• Fluoxetine: long half-life and active metabolite norfluoxetine — lactation implications; considered with reproductive psychiatry input
• Citalopram, escitalopram: additional lactation-compatible options
• SNRIs (venlafaxine, duloxetine): case-by-case
• Bupropion: can affect milk supply; case-by-case

For psychedelic-assisted therapy planning purposes, antidepressant decisions during pregnancy and lactation are perinatal psychiatry decisions — not psychedelic-clinic decisions. If a postpartum patient anticipates psychedelic-assisted therapy after weaning, antidepressant tapering planning is integrated with perinatal psychiatry oversight.

For more detail, see Antidepressant Tapering and Psychedelic-Assisted Therapy.

Mother-infant bonding considerations

Perinatal mental health treatment outcomes include the dyadic relationship — bonding, responsive caregiving, and infant attachment trajectory. Treatments that disrupt the dyad (extended separation, sedation that prevents responsive caregiving, treatments incompatible with breastfeeding) carry costs that must be weighed alongside symptom benefit.

This framing is one of several reasons standard first-line perinatal mental health treatments are favoured: psychotherapy and lactation-compatible pharmacotherapy generally support the dyad. Psychedelic-assisted therapy involves dosing-day windows incompatible with caregiving and a temporary inability to safely care for an infant — a logistical and clinical barrier above and beyond the pharmacological exclusion considerations.

Bipolar peripartum-onset and contraindication considerations

Peripartum onset of bipolar disorder is common — first manic, hypomanic, or mixed episodes may emerge in late pregnancy or the postpartum period, and pre-existing bipolar disorder frequently relapses peripartum. Postpartum psychosis is often a bipolar phenomenon.

Bipolar contraindication considerations apply to psilocybin and MDMA pathways — bipolar I and complex bipolar II are exclusions in pivotal RCTs. A patient with peripartum-onset bipolar disorder is not a candidate for psilocybin or MDMA SAP applications regardless of pregnancy/lactation status.

For more detail, see Bipolar Disorder and Psychedelic-Assisted Therapy — Considerations.

Family planning during a psychedelic-assisted therapy course

For patients of childbearing potential pursuing psychedelic-assisted therapy:

• Contraception during dosing windows — reliable contraception is recommended during a dosing course given the absence of human pregnancy safety data
• Pre-conception planning — patients planning conception are appropriately advised to complete the dosing and integration phases prior to attempting conception
• Cycle timing — for ketamine and Spravato courses, cycle awareness helps plan dosing
• Partner involvement — family-planning conversations are appropriately included in informed consent
• Documentation — pregnancy status check is standard pre-dosing for patients of childbearing potential in most clinical protocols

Practical timeline — when does psychedelic-assisted therapy fit?

Most psychedelic-assisted therapy pathways recommend completion before pregnancy or after weaning:

• Pre-conception: complete preparation, dosing, and initial integration before attempting conception
• Pregnancy: defer
• Postpartum, lactating: defer (with case-by-case ketamine consideration only under perinatal psychiatry oversight and with pump-and-discard protocol if pursued)
• Postpartum, weaned or non-lactating: reverts to standard adult considerations
• Inter-pregnancy interval: planning conversations reasonable

This timeline is honest and conservative. Emerging research will inform future practice.

Decision framework — perinatal psychedelic-assisted therapy

Perinatal crisis resources — Canada

If you or someone you support is experiencing a perinatal mental health crisis:

• 9-8-8 Canada Suicide Crisis Helpline — call or text 9-8-8 (24/7, all of Canada)
• Hospital emergency department — for any acute safety concern (postpartum psychosis is a psychiatric emergency)
• Postpartum Support International (PSI) — helpline 1-800-944-4773; text "Help" to 800-944-4773; PSI has Canadian coordinators
• Canadian Perinatal Mental Health Collaborative — clinician and family resources at https://cpmhc.ca/
• Provincial maternal/perinatal mental health services — every province has perinatal mental health pathways (BC Reproductive Mental Health Program, Women's College Hospital, CAMH, CHU Sainte-Justine, IWK)
• Pacific Postpartum Support Society — BC: 604-255-7999
• First Nations and Inuit Hope for Wellness Helpline: 1-855-242-3310 (24/7, multilingual)
• Local police 911 — if life-threatening emergency

These resources are foundational; psychedelic-assisted therapy is never an emergency intervention.

For more detail, see Suicidality and Psychedelic-Assisted Therapy.

What the evidence does NOT say

• No psychedelic-assisted therapy is approved for use in pregnancy or lactation in Canada.
• Pregnant and breastfeeding patients are excluded from virtually all pivotal RCTs — the published efficacy and safety base does not extend to this population.
• Spravato is not recommended in pregnancy or lactation per Health Canada label.
• Ketamine carries pregnancy caution and breastmilk presence per Health Canada label.
• Psilocybin and MDMA controlled human pregnancy and lactation data are absent — animal data are limited; MDMA animal data signal neurodevelopmental concerns.
• First-line perinatal mental health care has strong evidence — psychotherapy, sertraline, specialized perinatal psychiatry; standard of care is robust.
• Most psychedelic-assisted therapy is appropriately deferred until after pregnancy and lactation.
• Bipolar peripartum-onset triggers bipolar contraindication considerations for psilocybin/MDMA pathways.
• Mother-infant bonding is a treatment outcome — not just a constraint.

How ATMA CENA works with perinatal patients

ATMA CENA's clinical pathway for patients who are pregnant, postpartum, or breastfeeding:

• Comprehensive intake: full psychiatric and reproductive history; current pregnancy status; lactation status and infant age; specialized perinatal psychiatry connections; suicidality and crisis-resource grounding
• Honest framing: pregnancy and lactation are exclusions in pivotal RCTs; Health Canada Spravato and ketamine label cautions are explicit; psilocybin and MDMA controlled human perinatal data are absent
• Specialized perinatal psychiatry routing: where active perinatal mental health needs are present, referral to specialized perinatal psychiatry (BC Reproductive Mental Health Program, Women's College Hospital, CAMH, CHU Sainte-Justine, IWK) is the appropriate pathway
• First-line treatment confirmation: psychotherapy access, lactation-compatible pharmacotherapy review, perinatal mental health team engagement
• Family planning timeline: pre-conception or post-weaning timing of any future PAT course; integration with reproductive planning
• Postpartum, non-lactating: standard adult considerations apply; full intake proceeds
• Crisis resources foundational: 9-8-8, Postpartum Support International, provincial perinatal services
• No SAP applications in pregnancy or lactation: ATMA CENA does not support psilocybin or MDMA SAP applications during pregnancy or lactation
• Care coordination: with family physician, obstetrician/midwife, perinatal psychiatrist, lactation consultant where applicable

For more detail, see Postpartum Depression and Psychedelic-Assisted Therapy, Treatment-Resistant Depression and Psychedelic-Assisted Therapy, Family Members and Loved Ones Guide.

Frequently asked questions

Can I do ketamine therapy while pregnant? Ketamine therapy during pregnancy is generally deferred. The Health Canada ketamine product monograph flags pregnancy caution; uterotonic effects are documented. If a perinatal psychiatry team identifies a clinical situation in which ketamine is judged appropriate, this is delivered in specialized obstetric/psychiatric settings, not adult outpatient KAP clinics.

Can I do ketamine therapy while breastfeeding? Ketamine is present in breastmilk, and lactation pharmacokinetic data are limited. If ketamine is pursued during lactation, a pump-and-discard protocol around dosing is the conventional risk-mitigation approach, with timing guided by ketamine pharmacokinetics and infant age, under perinatal psychiatry/pharmacology and lactation-consultant oversight. Most patients defer until weaning.

Can I do Spravato while pregnant or breastfeeding? No. The Health Canada Spravato product monograph specifies that Spravato is not recommended in pregnancy or during breastfeeding.

Can I do psilocybin therapy while pregnant or breastfeeding? Psilocybin therapy during pregnancy or lactation is not currently appropriate. Controlled human pregnancy and lactation pharmacokinetic data are absent. SAP applications in pregnancy or lactation would face significant clinical resistance. ATMA CENA does not support psilocybin SAP applications during pregnancy or lactation.

Can I do MDMA-assisted therapy while pregnant or breastfeeding? MDMA-assisted therapy during pregnancy or lactation is not currently appropriate. Animal data signal neurodevelopmental concerns; controlled human pregnancy and lactation data are absent. ATMA CENA does not support MDMA SAP applications during pregnancy or lactation.

I have postpartum depression — can I do psychedelic-assisted therapy? First-line postpartum depression treatments include psychotherapy (CBT, IPT), sertraline (the most-studied SSRI in lactation), and specialized perinatal psychiatry. Psychedelic-assisted therapy is investigational for postpartum depression and is appropriately deferred until after weaning if pursued at all. See Postpartum Depression and Psychedelic-Assisted Therapy.

I'm planning to get pregnant — when should I do psychedelic-assisted therapy? Most pathways recommend completing the dosing and initial integration phases before attempting conception. A pre-conception planning conversation with your perinatal psychiatrist and your psychedelic-assisted therapy clinician helps align the timeline.

What about postpartum once I've stopped breastfeeding? Once lactation has safely concluded, perinatal-specific pharmacological exclusions resolve and standard adult psychedelic-assisted therapy considerations apply. Comprehensive intake, first-line treatment review, and bipolar peripartum-onset screening remain part of the standard pathway.

What about peripartum-onset bipolar disorder? Peripartum-onset bipolar disorder is common, and bipolar contraindication considerations apply to psilocybin and MDMA pathways. See Bipolar Disorder and Psychedelic-Assisted Therapy — Considerations. Postpartum psychosis is a psychiatric emergency requiring specialized inpatient care.

What antidepressants are compatible with breastfeeding? Sertraline is the most-studied and is generally first-line in lactation. Escitalopram and citalopram are additional lactation-compatible options. Paroxetine has historical first-trimester cardiac considerations. Fluoxetine has a long half-life and active metabolite with lactation implications. These are perinatal psychiatry decisions.

What perinatal crisis resources are available in Canada? 9-8-8 Canada Suicide Crisis Helpline (call or text); hospital emergency department for acute safety; Postpartum Support International 1-800-944-4773; Canadian Perinatal Mental Health Collaborative; provincial perinatal mental health services; First Nations and Inuit Hope for Wellness Helpline 1-855-242-3310.

Why does ATMA CENA defer psychedelic-assisted therapy during pregnancy and lactation? Pregnant and breastfeeding patients are excluded from virtually all pivotal psychedelic-assisted therapy RCTs. Health Canada Spravato and ketamine product monographs flag pregnancy and lactation cautions. Controlled human perinatal data for psilocybin and MDMA are absent. Specialized perinatal psychiatry first-line treatments have strong evidence bases. Honest framing supports deferral until after pregnancy and lactation.

Sources

1. Health Canada — Spravato (esketamine) Product Monograph (pregnancy and lactation sections): https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
2. Health Canada — Ketamine Product Monograph (pregnancy caution; uterotonic effects; breastmilk presence): https://health-products.canada.ca/dpd-bdpp/
3. MotherToBaby — Teratogenicity database (Organization of Teratology Information Specialists): https://mothertobaby.org/
4. Wisner KL, Sit DKY, McShea MC, et al. (2013). Onset Timing, Thoughts of Self-harm, and Diagnoses in Postpartum Women With Screen-Positive Depression Findings. JAMA Psychiatry, 70(5):490-498. PMID: 23487258.
5. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
6. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
7. Mitchell JM, Ot'alora G M, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473-2480. PMID: 37709999.
8. Anand A, Mathew SJ, Sanacora G, et al. (2023). Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression (ELEKT-D). New England Journal of Medicine, 388(25):2315-2325. PMID: 37224232.
9. CANMAT and CCMD Perinatal Mood and Anxiety Disorder Guidelines (Canadian Network for Mood and Anxiety Treatments): https://www.canmat.org/
10. BC Reproductive Mental Health Program — clinical pathways and resources: http://reproductivementalhealth.ca/
11. Canadian Perinatal Mental Health Collaborative: https://cpmhc.ca/
12. Postpartum Support International: https://www.postpartum.net/ (1-800-944-4773)
13. 9-8-8 Canada Suicide Crisis Helpline: https://988.ca/
14. Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access.html

Related articles

• Postpartum Depression and Psychedelic-Assisted Therapy — condition-hub for PPD framing
• Family Members and Loved Ones Guide
• Bipolar Disorder and Psychedelic-Assisted Therapy — Considerations — peripartum-onset bipolar
• Treatment-Resistant Depression and Psychedelic-Assisted Therapy
• Antidepressant Tapering and Psychedelic-Assisted Therapy — perinatal continuation considerations
• Psilocybin Therapy in Canada
• MDMA-Assisted Therapy in Canada
• Ketamine Therapy in Canada

Last updated: 2026-05-06